croi-2013-pocket-program

Tuesday
March 5 Oral Sessions
Session 21 CROI 2013
i Tuesday, 8:30-9 am; Hall B1
Session 21–Plenary
The Global MSM HIV Epidemic: Time to Act
71
Chris Beyrer
Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore,
MD, US
Objectives: This session is directed to clinicians, epidemiologists,
and scientists interested in HIV among MSM, HIV prevention, and
stigma and discrimination. It is assumed that participants are familiar
with both the epidemiology and risks for HIV infection among
these men in the US and in developing countries. At the completion
of the session, participants will be knowledgeable about why HIV
epidemics among gay, bisexual, and other MSM continue to expand
in 2013, and about what prevention and treatment approaches hold
promise for prevention and control.
j Tuesday, 9-9:30 am; Hall B1
Session 22–Plenary
Evolution of the Host–Virus Interaction: A Guide to
the Development of Novel Therapeutics?
72
Jonathan Stoye
MRC-Natl Inst for Med Res, London, UK
Objectives: This session is directed to clinicians and scientists
interested in the interaction between infecting retroviruses and
their targets. It is assumed that participants are familiar with basic
aspects of retrovirus replication. At the completion of the session,
participants will be knowledgeable about the properties of restriction
factors and ways in which this information might be used to devise
novel therapeutic strategies.
k Tuesday, 10 am-12 n; B406
Session 23–Oral Abstracts
HIV/SIV–Host Interaction
Moderators:
Eric Hunter, Yerkes Natl Primate Res Ctr, Emory Univ, Atlanta, GA, US
George Shaw, Univ of Pennsylvania, Philadelphia, US
10:00 73 Immunologic Profile Distinguishes Aviremic
HIV + Adults
Christina Ramirez Kitchen* 1 , P Hunt 2 , S Lee 2 , J Toyama 1 ,
E Sinclair 2 , L Epling 2 , P Hsue 2 , F Hecht 2 , J Martin 2 , and S Deeks 2
1 Univ of California, Los Angeles, US and 2 Univ of California, San
Francisco, US
10:15 74 Persistent Abnormalities of Lymphoid
Structures in HIV Viremic Controllers
Joyce Sanchez* 1 , P Hunt 2 , J Jessurun 1 , M Rothenberger 1 , C Reilly 1 ,
J Jasurda 1 , M Somsouk 2 , S Russ 1 , S Deeks 2 , and T Schacker 1
1 Univ of Minnesota, Minneapolis, US and 2 Univ of California, San
Francisco, US
10:30 75LB Prospective ART of Asymptomatic HIV + Controllers
Hiroyu Hatano* 1 , S Yukl 1,2 , A Ferre 3 , E Sinclair 1 , P Hunt 1 ,
P Bacchetti 1 , M Busch 1,4 , B Shacklett 3 , J Wong 1,2 , and S Deeks 1
1 Univ of California, San Francisco, US;; 2 San Francisco VA Med Ctr,
CA, US;; 3 Univ of California, Davis, US;; and 4 Blood Systems Res
Inst, San Francisco, CA, US
10:45 76 Effects of Interferon-� Treatment on Anti-HIV-1
Intrinsic Immunity in vivo
M Abdel-Mohsen 1 , T Liegler 1 , J Guatelli 2 , M Salama 3 , H Ghanem 3 ,
A Rauch 4 , B Ledergerber 5 , H Gunthard 5 , J Wong 1,6 , Satish Pillai* 1,6 ,
and Swiss HIV Cohort Study
1 Univ of California, San Francisco, US;; 2 Univ of California, San Diego,
US;; 3 Ain Shams Univ, Cairo, Egypt;; 4 Univ Hosp Berne, Switzerland;;
5 Univ Hosp Zurich, Switzerland;; and 6 VAMC, San Francisco, CA, US
10 � 20th Conference on Retroviruses and Opportunistic Infections
11:00 77 Blockade of Type I Interferon during Acute SIV
Infection Results in Accelerated Progression to
AIDS and Death
Netanya Sandler* 1 , R Zhu 1 , J Estes 2 , E Boritz 1 , J Lifson 2 ,
D Levin 3 , J Langer 4 , G Schreiber 3 , S Rao 1 , and D Douek 1
1 NIH, Bethesda, MD, US;; 2 NIH, Frederick, MD, US;; 3 Weizmann
Inst of Sci, Rehovot, Israel;; and 4 Univ of Med and Dentistry of New
Jersey and Robert Wood Johnson Med Sch, Piscataway, US
11:15 78 Experimental CD4 Depletion in SIV + Macaques
Results in Macrophage and Microglia Infection,
Rapid Turnover of Infected Cells, and Encephalitis
L Micci 1 , R Iriele 1 , X Alvarez-Hernandez 2 , C McGary 1 , C Derdeyn 1 ,
J Estes 3 , M Davenport 4 , A Lackner 2 , G Silvestri 1 , and Mirko Paiardini* 1
1 Yerkes Natl Primate Res Ctr, Emory Univ, Atlanta, GA, US;; 2 Tulane Natl
Primate Res Ctr, Covington, LA, US;; 3 AIDS Cancer Virus Prgm, NCI-
Frederick, MD, US;; and 4 Univ of New South Wales, Sydney, Australia
11:30 79 In vivo Evaluation of a Novel Variant of SIV mac
Lacking CD4 Tropism
Adrienne Swanstrom* 1 , B Haggarty 1 , A Jordan 1 , G Leslie 1 ,
X Alvarez-Hernandez 2 , C LaBranche 3 , D Montefiori 3 , P Marx 2 ,
A Lackner 2 , and J Hoxie 1
1 Univ of Pennsylvania, Philadelphia, US;; 2 Tulane Natl Primate Res
Ctr, Covington, LA, US;; and 3 Duke Univ, Durham, NC, US
11:45 80 Neutralization-sensitive Env with Exposed
Co-receptor Binding Sites Dominate in vivo
during SIV Infection of Macaques Depleted
of CD4 + T Cells
Nicholas Francella* 1 , Y Yi 1 , B Li 2 , S Gwyn 1 , S Elliott 1 ,
A Ortiz 2 , M Paiardini 2 , G Silvestri 2 , C Derdeyn 2 , and R Collman 1
1 Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US
and 2 Yerkes Natl Primate Ctr, Emory Univ, Atlanta, GA, US
k Tuesday, 10 am-12:15 pm; Ballroom 3-4
Session 24–Oral Abstracts
MTCT and HIV Treatment in Children
Moderators:
Denise Jamieson, CDC, Atlanta, GA, US
Denis Tindyebwa, African Network for Care of Children Affected by
AIDS, Kampala, Uganda
10:00 81 Birth Defects and ART in the French Perinatal
Cohort, a Prospective Exhaustive Study among
13,124 Live Births from 1994 to 2010
Jeanne Sibiude* 1 , L Mandelbrot 1,2,3 , S Blanche 4 , J Le Chenadec 3,5 ,
N Boullag-Bonnet 3 , A Faye 2,6 , C Dollfus 7 , R Tubiana 8 , B Khoshnood 9 ,
J Warszawski 3,5,10 , and ANRS CO1/CO10/CO11
1 Hosp Louis Mourier, Colombes, France;; 2 Univ Diderot Paris
7, Paris, France;; 3 CESP, INSERM U1018, Le Kremlin-Bicetre,
France;; 4 Hosp Necker, EA 3620, Univ Paris Descartes 5, Paris,
France;; 5 INED, Paris, France;; 6 Hosp Robert Debre, Paris, France;;
7 Hosp Trousseau, Paris, France;; 8 Hosp Pitie Salpetriere, INSERM
U943, Paris, France;; 9 INSERM, UMR S953, Univ Paris-6, Paris,
France;; and 10 Univ Paris Sud, Le Kremlin-Bicetre, France
10:15 82 Uptake and Retention in Malawis Option B+
PMTCT Program: Lifelong ART for All HIV +
Pregnant or Lactating Women
Beth Tippett Barr* 1 , E Mhango 2 , L Tenthani 2,3 , G Zomba 2,3 ,
S Makombe 2 , M Eliya 2 , D Midiani 2 , S Gupta 1 , F Chimbwandira 2 ,
and A Jahn 2,3
1 CDC, Lilongwe, Malawi;; 2 Ministry of Hlth, Lilongwe, Malawi;;
and 3 Intl Training and Ed Ctr for Hlth, Lilongwe, Malawi
10:30 83 Optimization of ART Initiation in Pregnancy
through Linkage of Services vs Integration of
ART into Antenatal Care
Landon Myer* 1 , V Manuelli 2 , E Abrams 3 , J McIntyre 1,4 , and L-G Bekker 1
1 Univ of Cape Town, South Africa;; 2 Obstetrics, Gynaecology and
Reproductive Sci, Univ of California, San Francisco, US;; 3 Intl
Ctr for AIDS Care and Treatment Prgm, Mailman Sch of Publ
Hlth, Columbia Univ, New York, NY, US;; and 4 Anova Hlth Inst,
Johannesburg, South Africa
10:45 84LB Efficacy and Safety of 6 Months vs 6 Weeks
Nevirapine for Prevention of Postnatal HIV-1
Transmission 18 Month Follow-up:
HPTN 046 Trial
Mary Glenn Fowler* 1 , H Coovadia 2 , E Brown 3 , L Stranix-Chibanda 4 ,
D Moodley 5 , R Kisenge 6 , P Richardson 1 , S Zwerski 7 , L Mofenson 8 , and
B Jackson 1
1 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; 2 Maternal
Adolescent and Child Hlth, Univ of the Witwatersrand, South Africa;;
3 Fred Hutchinson Cancer Res Ctr, Seattle, WA, US;; 4 Univ of Zimbabwe
Coll of Med, Harare;; 5 Ctr for the AIDS Prgm of Res in South Africa,
Nelson R Mandela Sch of Med, Univ of KwaZulu Natal, Durban;;
6 Muhimbili Univ of Hlth and Allied Sci, Dar es Salaam, Tanzania;;
7 NIAID, NIH, Bethesda, MD, US;; and 8 Eunice Kennedy Shriver Natl
Inst of Child Hlth and Human Devt, NIH, Rockville, MD, US